Auxilium Pharmaceuticals Inc

Auxilium Pharmaceuticals — Investor Presentation (March 2009)

48 slides from Auxilium Pharmaceuticals's investor presentation, Mar 19, 2009

  1. Slide 1: March 2009

    March 2009 Exhibit 99.1 (NASDAQ: AUXL)

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to market, size of market,

  3. Slide 3: Focused on Sustainable Long-term Growth

    Focused on Sustainable Long-term Growth Testim XIAFLEX Dupuytren’s XIAFLEX Peyronie’s XIAFLEX New Indications XIAFLEX New Territories

  4. Slide 4: Anticipated XIAFLEX Events 2009-2010

    • Decision from FDA on priority review (approx. 60 days post-BLA filing on Feb. 27) • Dupuytren's Contracture safety data available (post-BLA filing) • Top-line results of Peyronie's Phase IIb Study (4Q09) • FDA Approval In Dupuytren’s Contracture (early 2010) • U.S. Dupuytren’s Contracture Launch (

  5. Slide 5: Pipeline Continues to Advance

    Pipeline Continues to Advance TESTIM ® GEL XIAFLEX™ XIAFLEX™ XIAFLEX™ Transmucosal Film AA4010 Transmucosal Film Transmucosal Film Hormone & Urology Note: Seeking partners for Transmucosal film product candidates PRODUCT LATE RESEARCH PRE-CLINICAL PHASE I PHASE II PHASE III MARKET Hypogonadism Dupuy

  6. Slide 6: Strong Strategic Partner for XIAFLEX in EU Validates Market Potential

    Strong Strategic Partner for XIAFLEX in EU Validates Market Potential • Compelling economics for Auxilium: • Up-front payment of $75 million • $150 million tied to regulatory milestones • $260 million based on sales milestones • Significant increasing tiered royalties based on sales of XIAFLEX in Pf

  7. Slide 7: XIAFLEX Driver of Long-Term Growth

    XIAFLEX Driver of Long-Term Growth XIAFLEX product and packaging have not been approved by the FDA

  8. Slide 8: XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity

    XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity • Potential to be the only effective non-surgical treatment for two high unmet needs: – Dupuytren’s contracture – Peyronie’s disease • Well-characterized mode of action • State of the art biological manufacturing facility • Worldwide rights gener

  9. Slide 9: Dupuytren's Contracture is Debilitating for Patients

    Dupuytren’s Contracture is Debilitating for Patients • Excessive collagen deposition in fascia of hand • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Quality of life and daily activities can be significantly affected • Surgery may be rese

  10. Slide 10: Current Treatment Options Require Invasive Surgery or Are Unapproved and Ineffective

    Current Treatment Options Require Invasive Surgery with Significant Recuperation or Are Unapproved and Ineffective • Surgery • Non-surgical options > Splinting > Physical therapy > Corticosteroids • Needle fasciotomy/ aponeurotomy • Amputation

  11. Slide 11: XIAFLEX Offers an Improved Mechanism of Action

    XIAFLEX Offers an Improved Mechanism of Action • Clostridial collagenase is faster and more potent than human collagenase – Activity of XIAFLEX further enhanced by optimizing the ratio of collagenases in the product End products Fast cleavage Human collagenase Human collagenase (MMP) (MMP) Slow clea

  12. Slide 12: CORD I - Largest Double-blind, Placebo-controlled Trial in Dupuytren's Contracture

    CORD I - Largest Double-blind, Placebo- controlled Trial in Dupuytren’s Contracture • Primary endpoint is reduction in contracture to within - of normal > randomized in 2:1 ratio of active to placebo > enrolled a 2:1 ratio of MP:PIP > enrolled 1:1 ratio of less severe to more severe joints • Seconda

  13. Slide 13: PANY

    49.1 50.2 847% 3 — | SG — | PANY [—_ — | saeshieg quauranoiduyy yA (%) Wed. 3% ll 64% (3) ssazang ya juaaieg Innovations for tite”

  14. Slide 14: XIAFLEX Phase III AE and SAE Rates Compare Favorably To Surgical Complications

    XIAFLEX Phase III AE and SAE Rates Should Compare Favorably To Surgical Complications Tendon / Ligament: Confirmed Tendon Rupture 3 0.12% Ligament Injury 1 0.04% Total Tendon / Ligament 4 0.15% Deep Vein Thrombosis 1 0.04% Dupuytren’s Disease 1 0.04% Complex Regional Pain Syndrome 1 0.04% Total 7 0.

  15. Slide 15: XIAFLEX Offers a Non-Invasive Treatment for Dupuytren's Contracture

    XIAFLEX Offers a Non-Invasive Treatment for Dupuytren’s Contracture

  16. Slide 16: Dupuytren's Key Clinical Takeaways

    Dupuytren’s Key Clinical Takeaways • Efficacy should compare favorably to surgery – Primary endpoint of 5° reached with statistical significance in multiple studies – Secondary endpoints support commercial uptake • Less severe contractures responded better than more severe contractures • MP joints r

  17. Slide 17: XIAFLEX I.P. Position for Dupuytren's Contracture

    XIAFLEX I.P. Position for Dupuytren’s Contracture • U.S. Orphan Drug granted on May 23, 1996 provides exclusivity for 7 years post-approval • Market Exclusivity expected in EU for 10 years post-approval > Data protection granted for 8 years • Method of Use Patent in U.S. through 2014 • Use Patent in

  18. Slide 18: XIAFLEX Supply Chain

    XIAFLEX Supply Chain • API produced in Horsham, PA – 2 ° - 8 ° C storage expected at launch – Annual capacity at current yield should be sufficient for several years of global launch expectations – 1 manufacturing train in use and validated; capacity to expand for future demand • Fill and Lyophiliza

  19. Slide 19: Dupuytren's Contracture – an Unmet Medical Need

    Dupuytren’s Contracture –an Unmet Medical Need Tubiana 2006. Hueston 1963 Skoog 1948 Mikkelsen 1976 • Disease prevalence is estimated at 3%-6% of adult Caucasian population, or 13.5 to 27 Million, in U.S. and EU, but occurs in all populations – RA is 1% of adult population • Higher prevalence in pat

  20. Slide 20: Extensive Market Research Performed with Dupuytren's Surgeons

    Extensive Market Research Performed with Dupuytren’s Surgeons • Multiple prevalence data sets proved to be highly variable in numbers of patients • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Dupuytren’s contracture • A combined 571 Orthopedic Surgeo

  21. Slide 21: Annually, >240,000 Dupuytren's Candidates Could Exist between U.S. & EU

    Annually, >240,000 Dupuytren’s Candidates Could Exist between U.S. & EU Source: 2006 Auxilium research and analysis

  22. Slide 22: Commercial Target for Launch of XIAFLEX in Dupuytren's Contracture

    Commercial Target for Launch of XIAFLEX in Dupuytren’s Contracture Stage I Stage II Stage III Not Seeking Treatment 12.5-26 Million pts Medical and Surgical Treatment 395,000 pts Watchful Waiting 635,000 pts

  23. Slide 23: Sustainable Blockbuster Market for Dupuytren's Contracture Anticipated

    Sustainable Blockbuster Market for Dupuytren’s Contracture Anticipated • High disease prevalence – Based on literature, ~ 13.5M to 27M patients in U.S. and EU, however only ~ 1M patients annually seeking treatment in U.S. and EU • Sustainable patient pool – New patients within an ageing population •

  24. Slide 24: Peyronie's Disease is a Devastating Disorder

    Peyronie’s Disease is a Devastating Disorder Smith BH. Am J Clin Pathol . 1966;45:670 - 678. Somers KD, Dawson DM. J Urol . 1997;157:311-315. • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Symptoms > Pain with erection, penile curvature/

  25. Slide 25: Peyronie's Disease - an Unmet Medical Need

    Peyronie’s Disease - an Unmet Medical Need Schwarzer U, The prevalence of Peyronie’s disease: Results of a large survey. BJU Int 2001;88:727-30; Mulhall et al: J Urology 2004:171: 2350 - 2353;Rhoden et al: Int J. Impot Res 2001 :13 : 291 - 293; La Pera et al : EUR Urology 2001: 40 :525 - 530. Smith

  26. Slide 26: Current Surgical Options - Treatment of Last Resort

    Current Surgical Options- Treatment of Last Resort • The goal of surgery is simply to make the two sides of the penis equal in size through reduction of the longer side • Post-surgically, graft or prosthetic may be required • Cost of surgery in U.S. is ~$10-12K • Patients are highly motivated to att

  27. Slide 27: Unapproved Treatments for Peyronie's Disease Have Been Used With Little Reported Success

    Unapproved Treatments for Peyronie’s Disease Have Been Used With Little Reported Success • Verapamil • Vitamin E • Colchicine • Potassium aminobenzoate (Potaba) • Tamoxifen • Interferon alpha-2a • Corticosteroids • Energy transfer treatment including extracorporeal shock wave therapy (ESWT), laser a

  28. Slide 28: Study 1030 / Study 1035

    Study 1030 Percent of patients a-i-er Month 3 Month 6 Month 9 Study 1035 Tae : | Week6 Month3 Month6 Months a Innovations for tite”

  29. Slide 29: Peyronie's Phase IIb Study Top-line Data Expected in 4Q09

    Peyronie’s Phase IIb Study Top-line Data Expected in 4Q09 • Study designed to assess the safety and efficacy with XIAFLEX. – XIAFLEX will be administered two times a week every six weeks for up to three treatment cycles (2 x 3) – ~120 patients – 12 U.S. sites • Patients must be able to maintain a ri

  30. Slide 30: Peyronie's Phase IIb Study Design

    Peyronie’s Phase IIb Study Design A XIAFLEX yes 45 B Placebo yes 15 C XIAFLEX no 45 D Placebo no 15 120 Arm Study Drug Plaque Modeling Targeted Number of Patients • Patients will be randomized in a 3:1 ratio of XIAFLEX to placebo and a 1:1 ratio to receive penile plaque modeling or no modeling.

  31. Slide 31: Peyronie's Phase IIb Trial Utilizes a Novel Patient Reported Outcome (PRO)

    Peyronie’s Phase IIb Trial Utilizes a Novel Patient Reported Outcome (PRO) • Study is designed to validate Auxilium’s proprietary Peyronie’s Patient Reported Outcome (PRO) questionnaire. • PRO will measure four domains of patients’ sexual quality of life, over a 36 week period: – penile pain – Peyro

  32. Slide 32: Extensive Market Research Performed with Peyronie's Surgeons

    Extensive Market Research Performed with Peyronie’s Surgeons • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Peyronie’s disease • A combined 575 Urologists have been interviewed to estimate market size (415 in U.S.; 160 in Europe) and 383 have given fe

  33. Slide 33: Annually, >210,000 Peyronie's Candidates Could Exist between U.S. and Europe

    Annually , > 210,000 Peyronie’s Candidates Could Exist between U.S. and Europe Source: 2006 Auxilium research and analysis

  34. Slide 34: XIAFLEX I.P. Position for Peyronie's Disease

    XIAFLEX I.P. Position for Peyronie’s Disease • U.S. Orphan Drug granted on March 12, 1996 provides exclusivity for 7 years post-approval • Market Exclusivity in EU could be extended to 11 years on approval of additional indication • Method of Use Patent in U.S. through 2019 • Use Patent Granted in F

  35. Slide 35: Testim 1% Testosterone Gel: Near-Term Growth Driver

    Testim ® 1% Testosterone Gel: Near-Term Growth Driver

  36. Slide 36: Testim Remains the Fastest Growing Testosterone Replacement Therapy Gel

    Testim ® Remains the Fastest Growing Testosterone Replacement Therapy Gel *Mulligan T. et al. Int J. Clin Pract 2006 • Proprietary, topical 1% testosterone gel > Once-a-day application > Favorable clinical and commercial profile • Recent study indicates 39% of U.S. males over 45 yrs are hypogonadal*

  37. Slide 37: Patient Results Were Proven in Clinical Studies

    Patient Results Were Proven in Clinical Studies Total Testosterone Free Testosterone Note: Adjusted geometric means (CV b %) of a single-dose (50 mg testosterone), randomized, complete crossover study of 29 hypogonadal men. 2,000 3,000 4,000 5,000 6,000 Mean AUC 0 - 24 (ng*h/dL) Testim AndroGel Mean

  38. Slide 38: Gels Continue to Drive Significant Growth in TRT Marketplace

    Gels Continue to Drive Significant Growth in TRT Marketplace Source: IMS data $35 $117 $200 $287 $340 $383 $449 $690 $563 $49 $59 $77 $118 $210 $302 $399 $459 $499 $568 $685 $819 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 Gel Patch Oral Injectables ($ in millions) Gel Segment Growth

  39. Slide 39: & a) = = S $ o cc z 2005 TRX (in thousands) 2006

    & a) 3 = = S $ o cc 3 z 2005 TRX (in thousands) 2006 2007 Hl Net Revenues ($ in millions) fotal RXs (000's) Sg 6 x ! 3 $

  40. Slide 40: Testim Patent Coverage

    Testim Patent Coverage *Note: The referenced Testim patents are owned by CPEX Pharmaceuticals, Inc. U.S. • U.S. Patent # 7,320,968* covering method of use claims for Testim issued January 22, 2008; expires 2025 • Divisional application and continuations filed with U.S. PTO in late 2007 with a plan t

  41. Slide 41: Q4 '08 Financial Results and 2009 Guidance

    Revenues $34.8 $125.4 $150-155 R&D Expense $14.6 $54.5 $49-53 SG&A Expense $24.4 $89.5 $116-121 Net Loss ($12.1) ($46.3) ($50-55) Stock – Based Comp Expense $3.7 $11.7 $16-19 Cash & Cash Equivalents $113.9 Q4 ‘08 Financial Results and 2009 Guidance ($ Millions) 2009 Q4 ’08 2008 Guidance Currently ap

  42. Slide 42: Strategic Priorities in 2009

    Strategic Priorities in 2009 • Continue our pre-launch commercialization efforts and, if FDA grants a priority review for the XIAFLEX BLA for Dupuytren’s contracture, be prepared to launch in ~60 days after anticipated approval date; • Release top-line data from the XIAFLEX Peyronie’s disease Phase

  43. Slide 43: Focused on Sustainable Long-term Growth

    Focused on Sustainable Long-term Growth Testim XIAFLEX Dupuytren’s XIAFLEX Peyronie’s XIAFLEX New Indications XIAFLEX New Territories

  44. Slide 44: Sell-side coverage

    Sell-side coverage • Jonathon Aschoff- Brean Murray • Scott Henry- Roth • Salveen Kochnover- Collins Stewart • Kimberly Lee- Pacific Growth • Lucy Lu- Citigroup • Aaron Mishel- TWP • John Newman- Oppenheimer • Josh Schimmer- FTN • Eric Schmidt- Cowen • Joe Schwartz- Leerink Swann • David Steinberg-

  45. Slide 45: Management Contact

    Management Contact James E. Fickenscher/CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 jfickenscher@auxilium.com William Q. Sargent Jr./ VP IR Auxilium Pharmaceuticals, Inc. (484) 321-5900 wsargent@auxilium.com

  46. Slide 46: Innovations for tite”

    Innovations for tite”

  47. Slide 47: Innovations for tite”

    Innovations for tite”

  48. Slide 48: March 2009

    March 2009 (NASDAQ: AUXL)

Auxilium Pharmaceuticals — Investor Presentation (March 2009) on 6ix